The prevalence and impact of sarcopenia in myeloproliferative neoplasms
Journal of Surgery and Medicine · 29.09.2023 · 7 (9) · 623-627
DOI: 10.28982/josam.7979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgery and Medicine, online erschienen am 29.09.2023. Verfasst von Yildiz Ipek und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Aim: Rapid identification of patients with myeloproliferative neoplasms (MPNs) is crucial for clinical decision-making and healthcare management. Sarcopenia is characterized by muscle loss and increases the risks for adverse outcomes; there is limited information in the literature regarding possible links between sarcopenia and MPNs. This study evaluated the frequency of sarcopenia in patients with MPNs and investigated whether biochemical or clinical features were associated with the development of sarcopenia.
Methods
Fifty-six BCR-ABL1-negative patients were included in this randomized prospective cohort research study. Muscle strength was measured using a handgrip dynamometer. Muscle mass was evaluated using a bioelectrical-impedance analyzer, and physical performance was evaluated via gait speed in a 6-minute walking test.
Results
The mean handgrip strength of the cohort was 27.7 kg, and 13 patients (23.2%) tested positive for low muscle strength. Mean muscle mass was found to be 7.58 (1.17) kg/m2, and seven patients (12.5%) exhibited low muscle mass. Three patients (5.4%) had low muscle quality. Nine patients (16.1%) were diagnosed with probable sarcopenia, and four patients (7.1%) were diagnosed with severe sarcopenia. There was no difference between the groups in terms of clinical features (P>0.05), nutritional assessment (macro and micronutrients) (P=0.959), comorbidities (P=0.476), or laboratory measurements (P>0.05).
Conclusion
There was a high prevalence of sarcopenia among patients with MPNs, which indicates that periodic measurements of muscle strength, body composition and physical performance may contribute to the management of MPNs.
Zitieren
APA
Ipek, Y., & Tuna, M. K. (2023). The prevalence and impact of sarcopenia in myeloproliferative neoplasms. Journal of Surgery and Medicine, 7(9), 623-627. https://doi.org/10.28982/josam.7979
Vancouver
Ipek Y, Tuna MK. The prevalence and impact of sarcopenia in myeloproliferative neoplasms. Journal of Surgery and Medicine. 2023;7(9):623-627. doi:10.28982/josam.7979
BibTeX
@article{Ipek2023,
author = {Ipek, Yildiz and Tuna, MüJgan Kaya},
title = {The prevalence and impact of sarcopenia in myeloproliferative neoplasms},
journal = {Journal of Surgery and Medicine},
year = {2023},
volume = {7},
number = {9},
pages = {623--627},
doi = {10.28982/josam.7979}
}
EUVIMED